Cargando…

Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain

SIMPLE SUMMARY: CAR T therapies axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have been approved in Spain for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), given their favourable outcomes for overall survival and progression-free survival. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bastos-Oreiro, Mariana, de las Heras, Ana, Presa, María, Casado, Miguel A., Pardo, Carlos, Martín-Escudero, Victoria, Sureda, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8833685/ https://www.ncbi.nlm.nih.gov/pubmed/35158805 http://dx.doi.org/10.3390/cancers14030538

Ejemplares similares

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
por: Kwon, Mi, et al.
Publicado: (2022)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
por: Dickinson, M., et al.
Publicado: (2022)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
por: Gagelmann, Nico, et al.
Publicado: (2023)

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
por: Bachy, Emmanuel, et al.
Publicado: (2022)

Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Choe, Jee H., et al.
Publicado: (2022)

Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma
por: Ghanem, Buthainah
Publicado: (2023)

Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
por: Schubert, Maria-Luisa, et al.
Publicado: (2020)

P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
por: Oluwole, Olalekan, et al.
Publicado: (2023)

Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review
por: Wu, XiaoQin, et al.
Publicado: (2021)

Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States
por: Parker, Christopher, et al.
Publicado: (2023)

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Jacobson, Caron, et al.
Publicado: (2023)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
por: Jallouk, Andrew P., et al.
Publicado: (2022)

Axicabtagene ciloleucel for B-cell lymphoma
Publicado: (2021)

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
por: Riedell, Peter A., et al.
Publicado: (2020)

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
por: Logue, Jennifer M., et al.
Publicado: (2020)

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
por: Kato, Koji, et al.
Publicado: (2021)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
por: Wudhikarn, Kitsada, et al.
Publicado: (2021)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
por: Badbaran, Anita, et al.
Publicado: (2020)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
por: Meng, Jun, et al.
Publicado: (2021)

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
por: Westin, Jason R., et al.
Publicado: (2023)

Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
por: Shah, Mili, et al.
Publicado: (2021)

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
por: Plaks, Vicki, et al.
Publicado: (2021)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
por: Jain, Michael D, et al.
Publicado: (2018)

P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
por: Locke, F. L., et al.
Publicado: (2022)

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
por: Hoogland, Aasha I., et al.
Publicado: (2021)

Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma
por: Whittington, Melanie D., et al.
Publicado: (2019)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
por: Wang, LI, et al.
Publicado: (2023)

Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
por: Oluwole, Olalekan O., et al.
Publicado: (2021)

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
por: Sandoval-Sus, Jose, et al.
Publicado: (2021)

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
por: Salles, Gilles, et al.
Publicado: (2022)

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2023)

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
por: Jain, Michael D., et al.
Publicado: (2023)

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Flinn, Ian W., et al.
Publicado: (2023)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
por: Strati, Paolo, et al.
Publicado: (2020)

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2021)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review
por: Sun, Zhen, et al.
Publicado: (2021)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
por: Mohty, Razan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ao0147u7sg3f7q6056dhckhs1j